AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00000513
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02955134
Drug: Chinese medicine prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
Trial: NCT02955134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
Trial: NCT00262080
Drug: Phosphate Buffer Saline (PBS),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given as three 1mL subcutaneous injections.
Trial: NCT02369198
Drug: TargomiRs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected.
Trial: NCT03239379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT04198129
Drug: Antibiotic treatment (Unasyn or Cleocin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
Trial: NCT04198129
Drug: Antibiotic treatment (Augmentin or Cleocin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
Trial: NCT02126293
Drug: Zinc Supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03065712
Drug: F-18 Fluoroestradiol
RxNorm normalized name: Fluoroestradiol F-18
DrugBank: Fluoroestradiol F-18 (DB15690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-18 Fluoroestradiol will be administered for PET/CT scan.
Trial: NCT06457035
Drug: immunosuppressant
RxNorm normalized name: Immunosuppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention was performed in this retrospective cohort study.
Trial: NCT03443726
Drug: 4% articaine 1:100.000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
Trial: NCT00357526
Drug: OCPs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04263142
Drug: GSK3640254 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Trial: NCT04263142
Drug: GSK3640254 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Trial: NCT00824187
Drug: EE20/DRSP(YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Trial: NCT00824187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert tablet
Trial: NCT00814372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02294149
Drug: mammalian Omega 3 Fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
Trial: NCT02294149
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712372
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 1-50 mg/g oral suspension
Trial: NCT02712372
Drug: AZD4831 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 placebo oral suspension
Trial: NCT01457118
Drug: NKTR-102 145 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Trial: NCT01457118
Drug: NKTR-102 120 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Trial: NCT01457118
Drug: NKTR-102 95 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Trial: NCT01457118
Drug: NKTR-102 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Trial: NCT04361643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
Trial: NCT00433732
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00869232
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 day 5-8
Trial: NCT04341675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02191787
Drug: Seresis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01718509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once-daily, orally, for up to 12 weeks
Trial: NCT00882999
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via Injection
Trial: NCT00882999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via Injection
Trial: NCT02293980
Drug: MK-3795
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02576964
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
Trial: NCT03364608
Drug: AS MDI 90 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS MDI 90 μg (2 actuations of 45 μg/actuation)
Trial: NCT01858155
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04556617
Drug: PLX2853
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX2853 tablets
Trial: NCT00258427
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg intravenously (IV) on Days -5 through -2.
Trial: NCT00365313
Drug: celecoxib, esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01469013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01469013
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally as background therapy
Trial: NCT00862849
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00862849
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00946946
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
Trial: NCT00946946
Drug: Azathioprine placebo
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4g Mesalazine tablets/day AND azathioprine placebo tablets
Trial: NCT00525148
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
Trial: NCT01614236
Drug: epidural
RxNorm normalized name: Epidural 17g 3.5"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be randomized similarly but will undergo surgery under epidural analgesia
Trial: NCT02686697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00807846
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 50 mg or 100 mg PO BID for 6 weeks
Trial: NCT00807846
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
Trial: NCT02733614
Drug: SRX246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: novel V1a receptor antagonist
Trial: NCT02733614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01737112
Drug: 99mTc-3PRGD2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Trial: NCT04301882
Drug: direct antiviral drugs (DAAs)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
Trial: NCT00908206
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single 175 mg oral dose of GSK598809.
Trial: NCT01638598
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo in each dose level
Trial: NCT03302416
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01638598
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1021958
Trial: NCT01769079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04355156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)
Trial: NCT00143221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03591146
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
Trial: NCT00357253
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
Trial: NCT04369430
Drug: AKST4290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral AKST4290
Trial: NCT04369430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT01251172
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03072121
Drug: SBP placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine \& placebo (for shexiang baoxin pill)
Trial: NCT02162485
Drug: Seretide Diskus with charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03047863
Drug: Cream without rhEGF
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Trial: NCT01996306
Drug: CPT-11 (Irinotecan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
Trial: NCT01996306
Drug: l-LV (dl-LV)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Trial: NCT01996306
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
Trial: NCT03443843
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally
Trial: NCT03443843
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray, 2 sprays per nostril
Trial: NCT00285298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03374514
Drug: Sterile isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile isotonic saline solution
Trial: NCT00305643
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
Trial: NCT00305643
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg given orally twice a day for each 21 day cycle.
Trial: NCT00305643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo twice daily on days 1-21
Trial: NCT00689819
Drug: Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
Trial: NCT00689819
Drug: Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
Trial: NCT03419767
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
Trial: NCT02180503
Drug: BI 1356 BS tablet - low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00818324
Drug: OPC-12759 Ophthalmic suspension
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation,4times/day,for 52weeks
Trial: NCT00734773
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
Trial: NCT00611897
Drug: N-acetylcysteine and ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (N-acetylcysteine)
Trial: NCT02444819
Drug: HM61713
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM61713 will be administered to evaluate efficacy and safety of subjects.
Trial: NCT00009815
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02528097
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
Trial: NCT02316756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo which will be given as oral suspension
Trial: NCT03811678
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet，administered orally once daily
Trial: NCT02934412
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
Trial: NCT04425772
Drug: FNC+Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
Trial: NCT04425772
Drug: FNC dummy tablet+Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
Trial: NCT03631862
Drug: CHOP Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
Trial: NCT03029650
Drug: Transderm Scop®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDDS dosage is 1.5 mg/72 hrs
Trial: NCT00696865
Drug: AZD2624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, 3 doses
Trial: NCT00696865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01187901
Drug: Sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
Trial: NCT01187901
Drug: Placebo A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
Trial: NCT01187901
Drug: Placebo B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
Trial: NCT01982604
Drug: TI-Inhalation Powder A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Insulin
Trial: NCT01588145
Drug: HM61713
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops